Endocrine therapy resistance in estrogen receptor (ER)-positive breast cancer.

Abstract

Estrogen receptor (ER)-positive breast cancer represents the majority (∼70%) of all breast malignancies. In this subgroup of breast cancers, endocrine therapies are effective both in the adjuvant and recurrent settings, although resistance remains a major issue. Several high-throughput approaches have been used to elucidate mechanisms of resistance and to derive potential predictive markers or alternative therapies. In this review, we cover the state-of-the-art of endocrine-resistance biomarker discovery with regard to the latest technological developments, and discuss current opportunities and restrictions for their implementation into a clinical setting.

• Authors: Tommaso De Marchi, John A Foekens, Arzu Umar, John W M Martens
• Journal: Drug discovery today (Drug Discov Today) Vol. 21 Issue 7 Pg. 1181-8 (07 2016) ISSN: 1878-5832 [Electronic] England
• PMID: 27233379 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2016 Elsevier Ltd. All rights reserved.

Chemical References

• Antineoplastic Agents, Hormonal
• Biomarkers, Tumor
• Estrogen Antagonists
• Receptors, Estrogen

Topics

• Antineoplastic Agents, Hormonal (therapeutic use)
• Biomarkers, Tumor (metabolism)
• Breast Neoplasms (drug therapy, metabolism)
• Drug Resistance, Neoplasm
• Estrogen Antagonists (therapeutic use)
• Humans
• Receptors, Estrogen (metabolism)
• Treatment Outcome